US restrictions on international travel will be lifted November 8 for fully vaccinated international visitors and temporary workers, including those from nearly three dozen nations who have been barred from entering the country since the start of the pandemic. US citizens and permanent residents remain subject to current COVID-19 testing requirements.
This alert is an update to our Immigration Alert of October 19, 2021.
The Biden-Harris administration on October 25 announced that the presidential proclamations restricting entry to the United States will be rescinded, effective 12:01 am EST on November 8, 2021, and that new guidelines will take effect that suspend the entry of unvaccinated noncitizen nonimmigrants, except in limited circumstances.
As of the effective date, all noncitizens who are nonimmigrants (e.g., visitors, work visas, students, exchange visitors, etc.) traveling to the United States by air will be subject to new entry requirements. Those who are seeking entry at a land and/or sea port of entry will not be subject to the new guidelines. These new measures will also not apply to travelers who are onboard a US-bound flight that departed before the effective time and date.
As of 12:01 am EST on November 8, 2021, all noncitizen air travelers must
Such individuals must also agree to comply with all applicable public health precautions established by the director of the Centers for Disease Control (CDC).
Any noncitizen air traveler who is not fully vaccinated and who is admitted pursuant to the limited exceptions must agree to become vaccinated against COVID-19 within 60 days of arrival, or pursuant to a timeframe established by the CDC director. Such individuals must provide proof that they have made arrangements to become vaccinated prior to departing for the United States. Exceptions to this requirement, as determined by the CDC director, include the following:
The COVID-19 vaccination and testing requirement does not apply to the following classifications of noncitizen individuals:
All guidelines set forth above are subject to determinations made by the CDC director and will remain in effect until terminated by the US president. The CDC continues to update its guidance related to international travel and implementation of the proclamation on its international travel website.
The proclamation emphasizes that the new guidelines apply to questions of entry or admissibility, but do not impact visa issuance.
Accordingly, individuals should not be required to provide proof of adherence to the above-noted guidelines during visa appointments, and consular scheduling and adjudication of visa applications should not be negatively impacted by the proclamation. Evidence of compliance will be required at the time of boarding and at the time of inspection for admission in the United States.
Airlines have been directed to deny boarding to noncitizens who do not comply with the above-noted measures. Individuals experiencing extensive wait times for a National Interest Exception (NIE) to the current admission bans are recommended to reschedule their flights to enter the United States after November 8.
US citizens and lawful permanent residents are not impacted by this proclamation. However, they remain subject to already-existing CDC-mandated testing requirements.
As noted in our prior alert, “fully vaccinated,” for purposes of the new entry requirements, means that individuals must have completed a two-week period following the second dose of a two-dose series (such as Pfizer/BioNTech or Moderna vaccines), or a single-dose vaccine (such as the Johnson & Johnson vaccine).
Travelers must be fully vaccinated with vaccines approved or authorized for emergency use by the US Food and Drug Administration (FDA), or those that have been listed for emergency use by the World Health Organization (WHO). Such vaccines currently include Moderna, Pfizer/BioNTech, Janssen (Johnson & Johnson), AstraZeneca (Vaxzevria), Covishield, Sinopharm, and Sinovac. Sputnik V, developed by the Gamaleya National Center, has not yet been authorized. Certain AstraZeneca and Novavax COVID-19 vaccine clinical trial participants also qualify for entry under the new guidance.
The CDC has advised that mixed doses of COVID-19 vaccines will be acceptable for purposes of evidencing full vaccination. Such situations include instances in which the first dose was administered with a Pfizer/BioNTech vaccine, and the second dose was given as a Moderna vaccine.
Read more on COVID-19 vaccination travel guidelines.
If you have any questions or would like more information on the issues discussed in this alert, please contact any of the following Morgan Lewis lawyers:
Washington, DC
Shannon A. Donnelly
Eleanor Pelta
Eric S. Bord
Miami
Laura C. Garvin
For additional government-related guidance, learn more about our Washington strategic government relations and counseling practice.